Alkermes Inc.

Clinical activity includes separate research efforts in narcolepsy type 1 and narcolepsy type 2, indicating focused attention on the different clinical presentations of central hypersomnolence disorders.

• Cataplexy-associated narcolepsy
• Sleepiness-related impairment
• Central disorders of hypersomnolence

These studies center on symptoms that affect daily alertness and functional capacity in people living with narcolepsy.

Alkermes also funds research in idiopathic hypersomnia, a condition marked by persistent excessive daytime sleepiness and difficulty maintaining wakefulness.

• Daytime sleepiness
• Wakefulness disorders
• Sleep-related impairment

This area of interest aligns with therapeutic development for patients whose symptoms extend beyond nocturnal sleep disturbance to sustained daytime impairment.

The sponsor’s clinical research landscape emphasizes treatment of excessive daytime sleepiness across multiple hypersomnolence disorders, including narcolepsy and idiopathic hypersomnia.

• Alertness
• Daytime functioning
• Sleep-wake balance

Research activity spans multiple active sites and countries, supporting investigation of therapies aimed at improving wakefulness-related symptoms in these patient groups.